EXPLAINED: 2 - The Real Truth

1 Cathie Wood Stock With Over 100% Upside, According to Analysts

This biotech stock under $10 is the newest addition to Cathie Wood's flagship ARKK fund - and Wall Street analysts have high hopes for the shares, too.

Barchart · Dec 1, 2023

Benzinga's Top Ratings Upgrades, Downgrades For September 16, 2022

 

Benzinga · Sep 16, 2022

Recursion Pharmaceuticals's Return On Capital Employed Insights

Recursion Pharmaceuticals (NASDAQ:RXRX) brought in sales totaling $2.53 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 36.91%, resulting in a loss of $64.93 million.

Benzinga · Mar 24, 2022